O	0	4	Long
O	4	5	-
O	5	9	term
O	10	16	safety
O	17	19	of
O	20	31	intravenous
B-intervention	32	42	ibandronic
I-intervention	43	47	acid
O	48	51	for
O	52	54	up
O	55	57	to
O	58	59	4
O	60	65	years
O	66	68	in
O	69	79	metastatic
O	80	86	breast
O	87	93	cancer
O	93	94	:
O	95	97	an
O	98	102	open
O	102	103	-
O	103	108	label
O	109	114	trial
O	114	115	.

O	116	123	Despite
O	124	129	their
O	130	140	widespread
O	141	144	use
O	145	147	in
O	148	158	metastatic
O	159	163	bone
O	164	171	disease
O	171	172	,
O	173	177	some
O	178	192	bisphosphonate
O	193	198	drugs
O	199	202	are
O	203	213	associated
O	214	218	with
O	219	226	adverse
O	227	233	events
O	234	235	(
O	235	238	AEs
O	238	239	)
O	239	240	,
O	241	253	particularly
O	254	259	renal
O	260	268	toxicity
O	268	269	,
O	270	276	adding
O	277	279	to
O	280	289	treatment
O	290	297	burdens
O	298	301	and
O	302	312	increasing
O	313	323	healthcare
O	324	329	costs
O	329	330	.

O	331	341	Ibandronic
O	342	346	acid
O	347	349	is
O	350	351	a
O	352	358	single
O	358	359	-
O	359	367	nitrogen
O	368	382	bisphosphonate
O	383	387	with
O	388	392	high
O	393	401	efficacy
O	402	409	against
O	410	414	bone
O	415	421	events
O	422	425	and
O	426	436	metastatic
O	437	441	bone
O	442	446	pain
O	446	447	,
O	448	451	and
O	452	453	a
O	454	459	renal
O	460	466	safety
O	467	474	profile
O	475	481	compar
O	481	482	-
O	483	487	able
O	488	490	to
O	491	495	that
O	496	498	of
O	499	506	placebo
O	506	507	.

O	508	510	In
O	511	515	this
O	516	521	study
O	521	522	,
O	523	526	the
O	527	533	safety
O	534	536	of
O	537	547	ibandronic
O	548	552	acid
O	553	556	was
O	557	565	examined
O	566	570	over
O	571	572	a
O	573	579	period
O	580	582	of
O	583	584	4
O	585	590	years
O	590	591	.

O	592	598	During
O	599	601	an
O	602	609	initial
O	610	612	96
O	612	613	-
O	613	617	week
O	618	624	period
O	624	625	,
B-eligibility	626	632	breast
I-eligibility	633	639	cancer
I-eligibility	640	648	patients
I-eligibility	649	653	with
I-eligibility	654	658	bone
I-eligibility	659	669	metastases
O	670	674	were
O	675	685	randomised
O	686	688	in
O	689	695	double
O	695	696	-
O	696	701	blind
O	702	709	fashion
O	710	712	to
B-control	713	720	placebo
O	721	723	or
O	724	734	ibandronic
O	735	739	acid
O	740	743	6mg
O	744	756	administered
O	757	759	by
O	760	771	intravenous
O	772	780	infusion
O	781	785	over
O	786	787	1
O	787	788	-
O	788	789	2
O	790	795	hours
O	796	801	every
O	802	803	3
O	803	804	-
O	804	805	4
O	806	811	weeks
O	812	814	as
O	815	819	part
O	820	822	of
O	823	824	a
O	825	835	previously
O	836	844	reported
O	845	850	phase
O	851	854	III
O	855	860	trial
O	861	862	(
O	862	864	MF
O	865	869	4265
O	870	875	study
O	875	876	)
O	876	877	.

O	878	881	All
O	882	890	patients
O	891	901	completing
O	902	905	the
O	906	911	phase
O	912	915	III
O	916	921	trial
O	922	926	were
O	927	934	offered
O	935	939	open
O	939	940	-
O	940	945	label
O	946	952	active
O	953	962	treatment
O	963	966	for
O	967	968	a
O	969	976	further
O	977	979	96
O	980	985	weeks
O	986	987	(
O	987	996	extension
O	997	1002	phase
O	1002	1003	)
O	1003	1004	.

O	1005	1006	A
O	1007	1012	total
O	1013	1015	of
B-total-participants	1016	1018	62
O	1019	1027	patients
O	1028	1036	received
O	1037	1047	ibandronic
O	1048	1052	acid
O	1053	1056	6mg
O	1057	1059	in
O	1060	1064	this
O	1065	1074	extension
O	1075	1080	phase
O	1081	1084	and
O	1085	1089	were
O	1090	1100	classified
O	1101	1110	according
O	1111	1113	to
O	1114	1119	their
O	1120	1127	initial
O	1128	1137	treatment
O	1138	1139	(
O	1139	1146	placebo
O	1146	1147	/
O	1147	1157	ibandronic
O	1158	1162	acid
O	1163	1166	6mg
O	1167	1168	[
O	1168	1175	placebo
O	1175	1176	/
O	1176	1179	6mg
O	1179	1180	]
O	1181	1184	and
O	1185	1195	ibandronic
O	1196	1200	acid
O	1201	1204	6mg
O	1204	1205	/
O	1205	1215	ibandronic
O	1216	1220	acid
O	1221	1224	6mg
O	1225	1226	[
O	1226	1229	6mg
O	1229	1230	/
O	1230	1233	6mg
O	1233	1234	]
O	1235	1241	groups
O	1241	1242	)
O	1242	1243	.

O	1244	1250	Safety
O	1251	1254	was
O	1255	1263	assessed
O	1264	1266	by
O	1267	1269	AE
O	1270	1277	reports
O	1278	1281	and
O	1282	1290	clinical
O	1291	1301	laboratory
O	1302	1313	evaluations
O	1313	1314	.

O	1315	1321	During
O	1322	1325	the
O	1326	1327	4
O	1327	1328	-
O	1328	1332	year
O	1333	1338	study
O	1338	1339	,
O	1340	1344	most
O	1345	1353	patients
O	1354	1365	experienced
O	1366	1368	at
O	1369	1374	least
O	1375	1378	one
O	1379	1381	AE
O	1381	1382	,
O	1383	1387	with
O	1388	1398	malignancy
O	1399	1410	progression
O	1411	1416	being
O	1417	1421	most
O	1422	1430	commonly
O	1431	1439	reported
O	1439	1440	.

O	1441	1448	However
O	1448	1449	,
O	1450	1455	fewer
B-outcome	1456	1465	treatment
I-outcome	1465	1466	-
I-outcome	1466	1473	related
I-outcome	1474	1477	AEs
O	1478	1482	were
O	1483	1491	reported
B-outcome	1492	1494	in
I-outcome	1495	1498	the
I-outcome	1499	1508	extension
I-outcome	1509	1514	phase
O	1515	1516	(
O	1516	1523	placebo
O	1523	1524	/
O	1524	1527	6mg
O	1527	1528	:
B-cv-bin-percent	1529	1530	6
I-cv-bin-percent	1530	1531	.
I-cv-bin-percent	1531	1532	3
I-cv-bin-percent	1532	1533	%
O	1534	1535	[
B-cv-bin-abs	1535	1536	1
O	1536	1537	/
B-control-participants	1537	1539	16
O	1539	1540	]
O	1540	1541	;
O	1542	1545	6mg
O	1545	1546	/
O	1546	1549	6mg
O	1549	1550	:
B-iv-bin-percent	1551	1553	13
I-iv-bin-percent	1553	1554	.
I-iv-bin-percent	1554	1555	0
I-iv-bin-percent	1555	1556	%
O	1557	1558	[
B-iv-bin-abs	1558	1559	6
O	1559	1560	/
B-intervention-participants	1560	1562	46
O	1562	1563	]
O	1563	1564	)
O	1565	1569	than
B-outcome	1570	1572	in
I-outcome	1573	1576	the
I-outcome	1577	1584	initial
I-outcome	1585	1590	phase
O	1591	1593	of
O	1594	1597	the
O	1598	1603	study
O	1604	1605	(
O	1605	1612	placebo
O	1612	1613	:
B-cv-bin-percent	1614	1616	56
I-cv-bin-percent	1616	1617	.
I-cv-bin-percent	1617	1618	3
I-cv-bin-percent	1618	1619	%
O	1620	1621	[
B-cv-bin-abs	1621	1622	9
O	1622	1623	/
B-control-participants	1623	1625	16
O	1625	1626	]
O	1626	1627	;
O	1628	1631	6mg
O	1631	1632	:
B-iv-bin-percent	1633	1635	67
I-iv-bin-percent	1635	1636	.
I-iv-bin-percent	1636	1637	4
I-iv-bin-percent	1637	1638	%
O	1639	1640	[
B-iv-bin-abs	1640	1642	31
O	1642	1643	/
B-intervention-participants	1643	1645	46
O	1645	1646	]
O	1646	1647	)
O	1647	1648	.

O	1649	1656	Serious
B-outcome	1657	1660	AEs
O	1661	1665	were
O	1666	1672	mainly
O	1673	1676	due
O	1677	1679	to
O	1680	1690	malignancy
O	1691	1702	progression
O	1702	1703	.

O	1704	1709	There
O	1710	1714	were
O	1715	1717	no
O	1718	1728	clinically
O	1729	1737	relevant
B-outcome	1738	1743	renal
I-outcome	1744	1747	AEs
O	1747	1748	,
O	1749	1752	and
O	1753	1755	in
O	1756	1760	both
O	1761	1767	groups
O	1767	1768	,
B-outcome	1769	1774	serum
I-outcome	1775	1785	creatinine
I-outcome	1786	1792	levels
O	1793	1797	were
O	1798	1805	similar
O	1806	1809	for
O	1810	1812	up
O	1813	1815	to
O	1816	1817	4
O	1818	1823	years
O	1823	1824	.

O	1825	1829	This
O	1830	1832	96
O	1832	1833	-
O	1833	1837	week
O	1838	1842	open
O	1842	1843	-
O	1843	1848	label
O	1849	1855	safety
O	1856	1865	extension
O	1866	1868	of
O	1869	1870	a
O	1871	1876	phase
O	1877	1880	III
O	1880	1881	,
O	1882	1889	placebo
O	1889	1890	-
O	1890	1900	controlled
O	1901	1906	trial
O	1907	1919	demonstrates
O	1920	1924	that
O	1925	1929	long
O	1929	1930	-
O	1930	1934	term
O	1935	1938	use
O	1939	1941	of
O	1942	1953	intravenous
O	1954	1964	ibandronic
O	1965	1969	acid
O	1970	1972	is
O	1973	1977	well
O	1978	1987	tolerated
O	1987	1988	.
